Literature DB >> 6419845

Suppression of secondary hyperparathyroidism in uraemia: acute and chronic studies.

N Muirhead, G R Catto, N Edward, S Adami, R M Manning, J L O'Riordan.   

Abstract

A study was conducted evaluating the response of serum parathyroid hormone to acute hypercalcaemia and long term administration of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in patients receiving maintenance haemodialysis. During infusion of elemental calcium 4 mg/kg/h over four hours in 12 patients not receiving vitamin D the concentration of serum amino terminal parathyroid hormone fell by 31-96% (mean 74.8 (SD 17.6)%) while that of carboxy terminal parathyroid hormone changed little. There was a strong inverse correlation between baseline serum calcium concentration and percentage fall in amino terminal parathyroid hormone during infusion (r = 0.88; p less than 0.001). In seven patients who received prolonged treatment with 1,25(OH)2D3 after calcium infusion there was a positive correlation between maximum percentage fall in amino terminal parathyroid hormone during infusion and the percentage fall in amino terminal parathyroid hormone after 1,25(OH)2D3 treatment (r = 0.79; p less than 0.05). The responsiveness of the parathyroid glands to changes in calcium in acute studies may be used to predict the efficacy of long term treatment with 1,25(OH)2D3. Patients in whom calcium infusion does not suppress parathyroid hormone may have true parathyroid autonomy and require early parathyroidectomy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6419845      PMCID: PMC1444518          DOI: 10.1136/bmj.288.6412.177

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  10 in total

Review 1.  The peripheral metabolism of parathyroid hormone.

Authors:  K J Martin; K A Hruska; J J Freitag; S Klahr; E Slatopolsky
Journal:  N Engl J Med       Date:  1979-11-15       Impact factor: 91.245

2.  Prevention and reversal of progressive secondary hyperparathyroidism in patients maintained by hemodialysis.

Authors:  W J Johnson; R S Goldsmith; J W Beabout; J Jowsey; P J Kelly; C D Arnaud
Journal:  Am J Med       Date:  1974-06       Impact factor: 4.965

3.  Successful medical management of osteitis fibrosa due to "tertiary" hyperparathyroidism.

Authors:  W M Vosik; C F Anderson; W P Steffee; W J Johnson; C D Arnaud; R S Goldsmith
Journal:  Mayo Clin Proc       Date:  1972-02       Impact factor: 7.616

4.  Non-suppressible secondary hyperparathyroidism in chronic progressive renal disease.

Authors:  E Slatopolsky; W E Rutherford; P E Hoffsten; I O Elkan; H R Butcher; N S Bricker
Journal:  Kidney Int       Date:  1972       Impact factor: 10.612

5.  Control of secretion of parathyroid hormone in secondary hyperparathyroidism.

Authors:  S Adami; N Muirhead; R M Manning; J H Gleed; S E Papapoulos; L M Sandler; G R Catto; J L O'Riordan
Journal:  Clin Endocrinol (Oxf)       Date:  1982-05       Impact factor: 3.478

6.  Experimental hyperparathyroidism from multiple isologous parathyroid transplants: homeostatic effect of simultaneous thyroid transplants.

Authors:  R F Gittes; I C Radde
Journal:  Endocrinology       Date:  1966-05       Impact factor: 4.736

7.  Studies of circulating parathyroid hormone in man using a homologous amino-terminal specific immunoradiometric assay.

Authors:  S E Papapoulos; R M Manning; G N Hendy; I G Lewin; J L O'Riordan
Journal:  Clin Endocrinol (Oxf)       Date:  1980-07       Impact factor: 3.478

8.  Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy.

Authors:  J W Coburn; A S Brickman; D J Sherrard; F R Singer; E G Wong; D J Baylink; A W Norman
Journal:  Proc Eur Dial Transplant Assoc       Date:  1977

9.  What is tertiary hyperparathyroidism?

Authors:  P J Somerville; D J Tiller; R A Evans
Journal:  Aust N Z J Med       Date:  1975-12

10.  Development of homologous immunological assays for human parathyroid hormone.

Authors:  R M Manning; G N Hendy; S E Papapoulos; J L O'Riordan
Journal:  J Endocrinol       Date:  1980-04       Impact factor: 4.286

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.